ClinicalTrials.gg
CompletedNCT06010693Updated Oct 30, 2024

A Study of Daridorexant in Chinese Patients With Insomnia Disorder

A Phase 3 interventional study of Daridorexant and Placebo in Insomnia Disorder, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Completed at 33 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
6th of 16
206 · median 165
Started
2023
with 1 other
Phase 3
5 of 16
none open now
Registered
10th of 16
by date
Lead sponsor
1 of 16
Jiangsu Simcere Pharmaceutical Co., Ltd.

Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 10th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About daridorexant

daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the efficacy and safety of 50 mg daridorexant in adult and elderly chinese patients with insomnia disorder.

Efficacy will be evaluated on objective and subjective sleep parameters .

03

Conditions studied

  • Insomnia Disorder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed prior to any study-mandated procedure.
  2. Male or female aged ≥ 18 years old, ≤75 years old.
  3. Insomnia disorder according to diagnostic and statistical Manual of Mental Disorder, Fifth Edition (®) criteria, as follows:

    3.1 The predominant complaint is dissatisfaction with sleep quantity or quality, associated with one (or more) of the following symptoms:

    • Difficulty initiating sleep
    • Difficulty maintaining sleep, characterized by frequent awakenings or problems returning to sleep after awakenings.
    • Early-morning awakening with inability to return to sleep. 3.2 The sleep disturbance causes distress or impairment in social, occupational, educational, academic, behavioral, or other important areas of functioning.

    3.3 The sleep difficulty occurs despite adequate opportunity for sleep. 3.4 The insomnia is not better explained by another sleep-wake disorder (e.g., narcolepsy, a breathing-related sleep disorder, a circadian rhythm sleep-wake disorder, a parasomnia).

    3.5 The insomnia is not attributable to the physiological effects of a substance (e. g., a drug of abuse, a medication) 3.6 Coexisting mental disorders and medical conditions do not adequately explain the predominant complaint of insomnia.

    3.7 Self-reported history of all the following on at least 3 nights per week and for at least 3 months prior to Visit 1: 3.7.1 ≥30 min to fall asleep, and 3.7.2 Wake time during sleep ≥ 30 min, and 3.7.3 Subjective Total Sleep Time (sTST)≤6.5 h

  4. Insomnia Severity Index© score≥15
  5. Ability to communicate well with the investigator, to understand the study requirements and independently complete the study, as judged by the investigator, to be alert and oriented to person, place, time, and situation.
  6. Meeting all the following sleep parameters on at least 3 nights out of 7 nights on the eDiary completed at home between Visit 3 and Visit 4:

    6.1 ≥ 30 min to fall asleep, and 6.2 Wake time during sleep ≥ 30 min, and 6.3 sTST of ≤ 6.5 h

  7. Usual bedtime between 20:30 and 00:30 as reported on sleep diary completed between Visit 3 and Visit 4.
  8. Regular time in bed between 6 and 9 h as reported on sleep diary completed between Visit 3 and Visit 4.
  9. Meeting all the following sleep parameters on the 2 PSG nights at Visit 4:

    9.1 Mean Latency to Persistent Sleep (LPS) ≥ 20 min (with neither of the two nights \< 15 min), and 9.2 Mean Wake After Sleep Onset (WASO) ≥ 30 min (with neither of the two nights \< 20 min), and 9.3 Mean Total Sleep Time (TST) \< 420 min

  10. For women of , the following are required:

    • Negative serum pregnancy test (Visit 1).
    • Negative urine pregnancy test (Visit 3, Visit 5).
  11. Female and male subjects agree to use the scheme as required by the protocol from Screening visit up to at least 30 days after last D B study treatment intake, and have no plans to become pregnant, planned parenthood or sperm/egg donation plans, unless they have been sterilization surgically (with surgery at least 1 month before dosing), or female are (female subjects with natural menopause ≥12 months, ≥ 50 years old, can be considered postmenopausal after exclusion of pregnancy and other disorders that may cause amenorrhea; If age \<50 years by follicle stimulating hormone level confirmed).

Exclusion criteria

Exclusion Criteria:

  1. , or any lifetime history of sleep-related breathing disorderlike sleep apnea.
  2. Cognitive behavioral therapy (CBT) for any indication is allowed only if the CBT started at least 1 month prior to Visit 4 and the subject agrees to continue this CBT throughout the study.
  3. Self-reported usual daytime napping ≥ 1 h per day, and ≥ 3 days per week.
  4. Acute or unstable psychiatric conditions (including but not restricted to anxiety disorder, major depression, bipolar disorder, schizophrenia, obsessive compulsive disorder, or depression) that are diagnosed by the Mini International Neuropsychiatric Interview© or that require pharmacological treatment for these disorders. N.B.: subjects with a history of major depressive disorder currently without any symptoms and not requiring treatment are eligible.
  5. © score \< 25 in subjects ≥ 50 years.
  6. Shift work within 2 weeks prior to the screening visit, or planned shift work during the study.
  7. Travel across ≥ 3 time zones within 2 weeks prior to the screening visit, or planned travel across ≥ 3 time zones during the study.
  8. Treatment with central nervous system-active drugs, including over-the- counter medication and herbal medicines, are prohibited by this protocol within 5 half-lives of the respective drug (or 2 weeks, whichever is longer) prior to Visit 1, and until 24 h after the end of treatment (the end of the run-out period).
  9. Diagnosis of alcohol or substance use disorder within 2 years prior to the screening visit or inability to refrain from drinking alcohol for at least 3 consecutive days.
  10. Heavy tobacco use (at least one pack of cigarettes a day or inability to refrain from smoking during the night).
  11. Caffeine consumption ≥ 600 mg per day or any caffeine consumption after 4 pm
  12. Use of traditional Chinese medicine as prophylaxis or treatment of sleep disturbance within 4 weeks prior to Visit 1 and during the treatment phase.
  13. Treatment with another drug within 3 months prior to Visit 1, previous treatment with daridorexant or other orexin receptor antagonists (i.e. lemborexant, YZJ-1139) or previous randomization in any trial involving daridorexant
  14. Known or to drugs of the same class as the study treatment or to any of the study drug formulation.
  15. Not able or willing to stop treatment with moderate or strong cytochrome P450 (CYP)3A4 inhibitors, or treatment with moderate or strong inducers, within at least 1 week prior to Visit 3, until the end of treatment (the end of the run-out period).
  16. Not able or willing to stop consumption of grapefruit, Seville (bitter) oranges or juices from those fruits within at least 1 week prior to Visit 3, and until the end of treatment (the end of placebo run-out period).
  17. A prolonged calculated using Fridericia's formula (QTcF) interval (QTcF greater than 450 ms). If the QTcF is greater than 450 ms on the first single 12-lead , 2 additional 12-lead ECGs will be performed (at least after 30 min) and the mean of the 3 QTcF values will be calculated. (QTcF alculation formula seen in 11.5 Appendix)
  18. Periodic limb movement disorder with arousal index (PLMAI)

    ≥ 15/h (assessed on the 1st PSG night), restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy.

  19. Apnea/hypopnea index ≥ 15/h according to American Academy of Sleep Medicine criteria or event associated with blood oxygen saturation level by pulse oximetry (SpO2) \< 80%, as assessed on the 1st PSG night
  20. A history of moderate to severe hepatic impairment (eg, Class B or C). (details in 11.6 Appendix)
  21. Sleep diary completed less than 70% between Visit 3 to Visit 4, or at least 3 days out of the 7 days immediately preceding the first PSG of visit 4.
  22. Subjects who took placebo tablets less than 80% of days in from Visit 3 to Visit 4.

    Criteria assessed at Visit 1, Visit 2, Visit 3, Visit 4 and Visit 5

  23. Any of the following conditions related to suicidality:

    • Any suicidal ideation with intent, with or without a plan, at screening, i.e., answering "Yes" to questions 4 or 5 on the suicidal ideation section of the lifetime (Visit 1) and visit (Visit 2, Visit 3, Visit 4, Visit 5) version of the Columbia Suicide Severity Rating Scale© (C-SSRS©).
    • History of suicide attempt on the suicidal behavioral section of the lifetime version of the C-SSRS© (Visit 1).
  24. Coronavirus Disease 2019 (COVID-19) positive subjects, supported by Antigen test or Nucleic acid detection.
  25. For female subjects: pregnant, lactating or planning to become pregnant during projected duration of the study.
  26. Positive urine drug test or presence of alcohol in exhaled breath as detected by breathalyzer test.
  27. Unstable medical condition, significant medical disorder or acute illness, ECG, hematology or biochemistry test, thyroid function or coagulation test results within 1 month prior to the screening visit, which, in the opinion of the investigator, could affect the subject's safety or interfere with the study assessments.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    Daridorexant

    Participants will receive one daridorexant 50 mg tablet,orally, once daily for about 28 consecutive night on each night approximately 30 minutes before participants intends to try to sleep.

    Drug: Daridorexant

  • Placebo comparator
    Placebo

    Participants will receive one placebo matched to daridorexant 50 mg tablet,orally, once daily for about 28 consecutive night on each night approximately 30 minutes before participants intends to try to sleep.

    Drug: Placebo

Interventions

  • Participants will receive one Daridorexant 50mg tablet, orally, once daily for about 28 consecutive night on each night approximately 30mintues before participants intends to try to sleep.

  • DrugPlacebo

    Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.

06

What researchers measure

Primary outcomes

  1. The change from baseline to month 1 in wake after sleep onset (WASO) measured by polysomnography(PSG).

    Time frame: Baseline to last 2 night(night 27 and 28)

Secondary outcomes

  1. The change from baseline to the average of the last 7 days of month 1 in subjective total sleep time(sTST) measured by eDiary

    Time frame: Baseline to the average of the last 7 days of month 1

  2. The change from baseline to month 1 in latency to persistent sleep (LPS) measured by PSG.

    Time frame: Baseline to last 2 night(night 27 and 28)

Other outcomes

  1. Change from baseline to week 1 in the subjective total sleep time (sTST) measured by edairy.

    Time frame: Baseline to Week 1

  2. Change from baseline to month 1 in the objective total sleep time (TST) measured by PSG.

    Time frame: Baseline to last 2 night(night 27 and 28)

  3. Change from baseline to the last 7 days of month 1 in daytime functioning and alertness that is determined by scores on the visual analog scale (VAS ) at the end of the day.

    Time frame: Baseline to the average of the last 7 days of month 1

  4. Change from baseline to Month 1 in wake after sleep onset (WASO) over time measured by PSG.

    Time frame: Baseline to last 2 night(night 27 and 28)

  5. Change from baseline to the average of the last 7 nights of Month 1 in the subjective latency to sleep onset (sLSO) measured by eDiary.

    Time frame: Baseline to average of the last 7 days of Month 1

  6. The change from baseline to week 1 in subjective latency to sleep onset (sLSO) measured by eDiary.

    Time frame: Base line to Week 1

  7. Change from baseline to the last 7 nights of month 1 in subjective wake after sleep onset (sWASO) measured by eDiary.

    Time frame: Baseline to average of the last 7 days of month 1

  8. The change from baseline to week 1 in subjective wake after sleep onset(sWASO) measured by eDiary.

    Time frame: Baseline to Week 1

  9. Change from baseline to the last 7 days ofMonth 1/ Week 1 in sleep quality that is determined by scores on the visual analog scale(VAS) in the morning in eDiary.

    Time frame: Baseline to the average of the last 7 days of Month 1/ Week 1

  10. Change from baseline to the last 7 days of Month 1/ Week 1 in depth of sleep that is determined by scores on the VAS (mm) in the morning in eDairy.

    Time frame: Baseline to the average of the last 7 days of Month 1/ Week 1

  11. Change from baseline to the last 7 days of Month 1 / Week 1 in subjective number of awakenings measured by eDiary.

    Time frame: Baseline to the average of the last 7 days of Month 1/ Week 1

  12. Change from baseline to Month 1 in Insomnia Severity Index (ISI) total score. ©) total score

    Time frame: Baseline to month 1

  13. Change from baseline to Month 1 in sleep efficiency measured by PSG.

    Time frame: Baseline to month 1

  14. The next-morning plasma concentrations 9-10 hours post dose at the first and second night of Visit 7

    Time frame: Day 27/28 and Day 28/29

07

Study locations

33 sites
  • The Second People's Hospital Of Hefei
    Hefei, Anhui, China
  • Xuanwu Hospital of Capital Medical University
    Beijing, Beijing 100053, China
  • Beijing Huilongguan Hospital
    Beijing, Beijing, China
  • Peking University Sixth Hospital
    Beijing, Beijing, China
  • Chengdu Second People's Hospital
    Chengdu, Chengdu, China
  • Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Chongqing, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
  • Nanfang Hospital
    Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong, China
  • Hainan General Hospital
    Haikou, Hainan, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Nanjing Brain Hospital
    Nanjing, Jiangsu, China
  • The Second Hospital of Suzhou University
    Suzhou, Jiangsu, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
    Jinan, Shandong, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • Tai'an Central Hospital
    Tai'an, Shandong, China
  • Huashan Hospital Fudan University
    Shanghai, Shanghai, China
  • Shanghai Mental Health Center
    Shanghai, Shanghai, China
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • The Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Xianyang Hospital of Yan'an University
    Xianyang, Shanxi, China
  • Deyang People's Hospital
    Deyang, Sichuan, China
  • Tianjin Mental Health Center
    Tianjin, Tianjin, China
  • Tianjin People's Hospital
    Tianjin, Tianjin, China
  • Hangzhou Seventh People's Hospital
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2024, 7 months.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 7 months is below that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2023
First posted
Aug 24, 2023
StartActual
Aug 28, 2023
Primary completionActual
Apr 12, 2024
CompletionActual
May 10, 2024
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06010693
Responsible party
Sponsor
First posted
Aug 24, 2023
Start date
Aug 28, 2023
Primary completion
Apr 12, 2024
Completion
May 10, 2024
Last update
Oct 30, 2024

Study contacts

Yuping Wang, Doctor
principal investigator · Xuanwu Hospital of Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion